Close Menu

Regulus

Regulus Therapeutics has appointed Douglas Williams to its board of directors.

Mirna Therapeutics this week announced that it has closed a Series C round of financing, raising $34.5 million in what is the microRNA therapeutics field's biggest single round of private investment.

Shares of Regulus Therapeutics fell back near their already-reduced initial public offering level this week, suggesting that Wall Street may be less willing to embrace microRNA therapeutics than may have been anticipated.

Regulus Therapeutics, the microRNA drugs joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week disclosed that it is pricing its initial public offering of 11.25 million shares at $4 a share, for a total value of $45 million.

This article has been updated from a previous version to include background on previous IPOs in the RNAi/microRNA market.

Regulus Therapeutics, the microRNA drug joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, has filed with US regulators to begin selling its shares on the public market.

Regulus Therapeutics this week announced that it has formed a strategic alliance with AstraZeneca to discover, develop, and commercialize microRNA therapeutics against three exclusive targets.

NEW YORK (GenomeWeb News) – Regulus Therapeutics, a developer of microRNA-based therapeutics, announced after the close of the market Wednesday that it has signed a deal with Biogen Idec to identify blood-borne miRNA biomarkers for multiple sclerosis.

Title: Detection of Nucleic Acids
Patent Number: 8,206,904
Filed: June 1, 2007
Lead Inventor: Hatim Allawi, Third Wave Technologies

Regulus Therapeutics has appointed Bruce Carter to its board of directors.

Pages

NPR reports that many USDA researchers working at the two agencies that are relocating to the Kansas City area are declining to go.

Genetic genealogy has helped exonerate a man who has been jailed for 20 years, Agence France Presse reports.

A new report says genetically modified food might be necessary to be able to feed a planet of nearly 10 billion people, Bloomberg says.

In Nature this week: new RNA editing approach called LEAPER, draft assembly of Musa balbisiana banana genome, and more.